 Product Surveillance, Postmarketing
"Product Surveillance, Postmarketing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
| Descriptor ID |
D011358
|
| MeSH Number(s) |
E05.337.800
|
| Concept/Terms |
Product Surveillance, Postmarketing- Product Surveillance, Postmarketing
- Product Surveillance, Post-Marketing
- Post-Marketing Product Surveillance
- Post-Marketing Product Surveillances
- Product Surveillance, Post Marketing
- Product Surveillances, Post-Marketing
- Surveillance, Post-Marketing Product
- Surveillances, Post-Marketing Product
- Evaluation Studies, Postmarketing
- Evaluation Study, Postmarketing
- Postmarketing Evaluation Studies
- Postmarketing Evaluation Study
- Studies, Postmarketing Evaluation
- Study, Postmarketing Evaluation
- Postmarketing Product Surveillance
- Postmarketing Product Surveillances
- Product Surveillances, Postmarketing
- Surveillance, Postmarketing Product
- Surveillances, Postmarketing Product
Drug Surveillance, Postmarketing- Drug Surveillance, Postmarketing
- Drug Surveillances, Postmarketing
- Postmarketing Drug Surveillance
- Postmarketing Drug Surveillances
- Surveillance, Postmarketing Drug
- Surveillances, Postmarketing Drug
|
Below are MeSH descriptors whose meaning is more general than "Product Surveillance, Postmarketing".
Below are MeSH descriptors whose meaning is more specific than "Product Surveillance, Postmarketing".
This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in this website by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 3 | 0 | 3 | | 2012 | 3 | 2 | 5 | | 2013 | 5 | 4 | 9 | | 2014 | 1 | 2 | 3 | | 2015 | 4 | 3 | 7 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 3 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Duffy J, Marquez P, Moro P, Weintraub E, Yu Y, Boersma P, Donahue JG, Glanz JM, Goddard K, Hambidge SJ, Lewin B, Lewis N, Rouse D, Shimabukuro T. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 09; 71(49):1555-1559.
-
Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. JAMA Dermatol. 2020 10 01; 156(10):1066-1073.
-
Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011. JAMA Netw Open. 2020 08 03; 3(8):e2014496.
-
Dhruva SS, Parzynski CS, Gamble GM, Curtis JP, Desai NR, Yeh RW, Masoudi FA, Kuntz R, Shaw RE, Marinac-Dabic D, Sedrakyan A, Normand ST, Krumholz HM, Ross JS. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. J Am Heart Assoc. 2020 02 18; 9(4):e013606.
-
Saunders A, Messer LH, Forlenza GP. MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Rev Med Devices. 2019 Oct; 16(10):845-853.
-
Heiser C, Steffen A, Boon M, Hofauer B, Doghramji K, Maurer JT, Sommer JU, Soose R, Strollo PJ, Schwab R, Thaler E, Withrow K, Kominsky A, Larsen C, Kezirian EJ, Hsia J, Chia S, Harwick J, Strohl K, Mehra R. Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry. Eur Respir J. 2019 01; 53(1).
-
Bates J, Parzynski CS, Dhruva SS, Coppi A, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Shaw RE, Warner F, Krumholz HM, Ross JS. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. Pharmacoepidemiol Drug Saf. 2018 08; 27(8):848-856.
-
Czaja AS, Ross ME, Liu W, Fiks AG, Localio R, Wasserman RC, Grundmeier RW, Adams WG. Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias. Pharmacoepidemiol Drug Saf. 2018 07; 27(7):815-822.
-
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Alemtuzumab for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2018 03; 18(3):323-334.
-
Jones WS, Krucoff MW, Morales P, Wilgus RW, Heath AH, Williams MF, Tcheng JE, Marinac-Dabic JD, Malone ML, Reed TL, Fukaya R, Lookstein RA, Handa N, Aronow HD, Bertges DJ, Jaff MR, Tsai TT, Smale JA, Zaugg MJ, Thatcher RJ, Cronenwett JL. Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements. J Vasc Surg. 2018 02; 67(2):637-644.e30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|